Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.98), $0.12 worse than the analyst estimate of ($1.86).

Financial Guidance:

Based on its current plans, Blueprint Medicines expects that its existing cash, cash equivalents and investments, including the estimated net proceeds of approximately $327.2 million from its April 2019 follow-on public offering but excluding any potential option fees and milestone payments under its existing collaborations with Roche and CStone Pharmaceuticals, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the middle of 2021.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.